



**PHARMACEUTICAL ENGINEERING**  
**2018 Author Guidelines**

**EDITORIALS, FEATURES, AND SPECIAL REPORTS**

# Table of Contents

<b>Part I: Writing your article .....</b>	<b>4</b>
<b>Introduction .....</b>	<b>4</b>
<b>Editorial article types.....</b>	<b>4</b>
Editorials .....	4
Features .....	4
Special Reports .....	4
<b>Author information and copyright .....</b>	<b>4</b>
Name .....	4
Biography .....	4
Address .....	5
Signed copyright release .....	5
<b>Article content .....</b>	<b>5</b>
Original material .....	5
Accuracy and correctness .....	5
Commercialism.....	5
Legal and corporate review .....	5
Promise of publication .....	5
Editorial review .....	5
Final review .....	6
Acknowledgments .....	6
Text6	
<i>Editorial style</i> .....	6
Figures and graphics .....	6
Units of measure .....	6
Equations .....	6
Footnotes .....	6
References.....	7
Tables .....	7
<b>Part II: Using text and graphics from other sources .....</b>	<b>7</b>
Copyright.....	7
Plagiarism .....	8
<i>Self-plagiarism</i> .....	8
Copyright infringement .....	9
Using text copied from other sources .....	9
<i>Fair use</i> .....	9
<i>Public domain</i> .....	9
Using copied graphics .....	9

Securing permission to use a copyrighted work.....	10
<i>Published material</i> .....	10
<i>Company-supplied material</i> .....	11
Author rights to reuse material.....	11
<b>Part III: For more information.....</b>	<b>12</b>
<b>Contact .....</b>	<b>12</b>
<b>References .....</b>	<b>12</b>

# Part I: Writing your article

---

## Introduction

Thank you for agreeing to contribute to *Pharmaceutical Engineering*, the flagship magazine of the International Society for Pharmaceutical Engineers (ISPE), which inspires engineers around the world with provocative and useful articles from trustworthy and reliable sources. Our readers are professional engineers working across all facets of the pharmaceutical, biotechnology and manufacturing industries, as well as regulators, business leaders, academics, and students.

## Editorial article types

### Editorials

These are short, thought-provoking articles that provide a personal perspective on contemporary issues, hot topics, or controversies.

Maximum length: 1,000 words

### Features

These can cover recent industry developments, strategic issues, technical developments, trends, or innovative solutions.

Maximum length: 1,500 words, 2 figures

### Special Reports

Articles in Special Reports provide global perspectives on broad industry topics such as drug shortages, biotechnology, data integrity, quality metrics, and sustainability.

Maximum length: 3,000 words, 2 figures/photos

## Author information and copyright

Each author will receive a separate Author Information and Copyright file. You will not be listed in the article byline until you have submitted a completed file and a signed copyright release.

### Name

List your name as it should appear in the byline. You may include doctoral degrees and professional certifications. Company affiliations do not appear in the article byline.

### Biography

This should cover the highlights of your career in 150 words or less. Please include educational background, current title and company affiliation, responsibilities, and major areas of accomplishment.

### Address

Please list your full mailing and email addresses. Our mail house must have a complete mailing address to send author copies of the magazine to you after the issue has been published, and our editorial staff needs your email address to send review drafts and proofs.

### Signed copyright release

*ISPE retains copyright to all the articles it publishes.* All authors listed in the article byline must sign a copyright release and consent to publish form. Articles become the property of ISPE and may not be published elsewhere without written permission (see [Author rights to reuse material](#)).

## Article content

### Original material

Only original, complete, unpublished drafts will be considered for publication.

All graphic material—including tables, charts, and photographs—must be original and unpublished, or you must have permission from the source to reprint the image. For more information see the [Using copied graphics](#) sections.

### Accuracy and correctness

You and your coauthors are responsible for the accuracy and correctness of all statements in the article; ISPE assumes no liability.

### Commercialism

Commercialism is strictly prohibited.

- Commercialism is the inclusion of visual, written, or verbal references to any specific company and/or product for promotion or commercial advantage.
- The article must not promote a specific product or company to the exclusion of other similar products that could be used to resolve the problem.
- The article must focus on novel and innovative technical approaches to resolve a problem without excluding alternative options.

### Legal and corporate review

If you or any of your coauthors require legal and/or corporate review of the article before publication, you must indicate this when you submit the article.

### Promise of publication

There is no guarantee that a submitted article will be published. Publication depends on the assessment of our reviewers and the decision of the editor in chief.

### Editorial review

Every article submitted for publication in *Pharmaceutical Engineering* undergoes an editorial review for style, tone, flow, cohesion, and organization. ISPE has full editorial control of magazine content, and reserves the right to edit, revise, and delete copy as appropriate.

Following editorial review, the revised draft will be returned to you for review and approval.

#### Final review

You will receive a PDF of the article in preliminary layout for final sign-off.

#### Acknowledgments

If you include an acknowledgments section, you may place it at the end of the article.

#### Text

Article text must be in \*.doc or \*.docx format. PDFs, screenshots, or hard copy documents cannot be accepted.

#### *Editorial style*

*Pharmaceutical Engineering* follows the [Chicago Manual of Style, 17th edition](#), and [Scientific Style and Format, 8th edition](#), both published by the University of Chicago Press.

#### Figures and graphics

All image file formats **except Microsoft Visio** are acceptable. If your figures were created in Visio, you must export them as a high-resolution graphics file (JPG, BMP, TIFF, PNG, or PDF).

All image files must be suitable for print: 300 dpi or at least 1 MB.

- Graphs, charts, and tables created in Microsoft Excel or PowerPoint should be submitted in their original file format.
- Graphs, charts, and tables created in other mathematics graphing programs must be submitted as high-resolution PDFs or in another image file format.
- Screenshots will not be accepted.
- Each figure must include a brief caption.
- To make the article easier to review, insert figures and tables within the document; you may also upload them with your submission as separate files.

#### Units of measure

You may use either metric or imperial/avoirdupois measurements.

#### Equations

Simple equations may be displayed as regular text. Longer, more complex mathematics may be created using Microsoft Word's **Insert Equation** function.

#### Footnotes

Footnotes explain a term or concept, are flagged with a symbol instead of a number, and placed at the bottom of a page.

### Example

Both individuals and research groups were involved in identifying the CRISPR system in nature, then adapting it as a genome-editing technology.\*

### References

References list the information sources you used to write your article. They may be published, unpublished, or personal communications.

When you place a reference in the article text, number it and enclose the numeral in square brackets. These citations may be placed in the middle of a sentence, or *following* punctuation. (See the [Using Text and Graphics from Other Sources](#) section for examples.)

List all references at the end of the article, numbered in the order in which they appear. Include only those sources that you cite in the text. Please list as much information about each source as possible. You may use the [references at the end of this document](#) as a template for your own citations.

**Note:** *Don't copy references from other authors—they are often incorrect. Find and cite the original sources.*

### Tables

Create tables using the table function in Word.

- Include a caption for each table.
- Place significance values, other statistical data, and notes below the table.
- Include an attribution when the material has been copied from another source (see [Using copied graphics](#)).

## Part II: Using text and graphics from other sources

---

### Copyright

Copyright is a form of intellectual property law. It protects original works by requiring permission from the author (or publisher, who acquires rights from the author) to reuse or adapt it.

Copyright exists as soon as a work is “fixed in a tangible medium of expression” (including thumb drives and cocktail napkins); even unpublished works are protected by copyright. [1]

---

\* Briefly, repeated sequences of 30 bases separated by spacers of approximately 36 bases were identified in an archaeal microbe by Francisco Mojica in 1993. Over a decade later, Mojica realized that CRISPR loci are part of an adaptive defense system that protects microbes against specific infections.

As part of the scientific community, ISPE is committed to a fair editorial process that protects copyright for all authors and publishers. This upholds the foundation of trust at the heart of scientific scholarship and research, [2] and reduces the potential for copyright infringement, which may result in significant legal penalties.

### Plagiarism

Plagiarism is using another person’s work—copyrighted or not—and representing it as the product of your own effort. You may think it’s sufficient to make a few tweaks, change a few words, and cite the source from which you copied the text. But that’s still plagiarism.

You must *completely revise and restate* the idea(s) in your own words. Note that you must still document the source in which you found the information, and you must do this *for every item in the article that you took from another source*.

If you can’t or don’t want to do this, you must mark the copied material as a quotation—then add a reference and cite the source from which you copied the text.

#### **Original**

The emergence of "big data" has allowed pharmaceutical organizations to harness the vast amount of information they generate. [1]

#### **Insufficient tweak**

"Big data" has allowed pharmaceutical organizations to harness the information they generate. [1]

#### **Revise and restate**

As metrics and statistics have evolved into “big data,” the pharmaceutical industry has learned how to tap the enormous reservoirs of information it produces. [1]

#### **Quotation**

As Ingram et al. noted, “The emergence of ‘big data’ has allowed pharmaceutical organizations to harness the vast amount of information they generate.” [1]

-----  
 1. Ingram, Marzena, et al. “Manufacturing Excellence Utilizing a Life Cycle Approach.” *Pharmaceutical Engineering* 37, no. 5 (September-October 2017): 69–69.

Why is plagiarism wrong—even if the material is drawn from a [public domain](#) source? Because *Pharmaceutical Engineering* publishes original thought, research, and content. Failing to disclose copied material and presenting it as original work perpetrates a fraud on our readers and undermines our integrity as a publisher of scientific and technical knowledge.

### *Self-plagiarism*

Authors who have published books or articles usually do not own the copyright to those materials. Most publishers, however, grant authors the right to reuse their published work (see the [Taylor and Francis](#) and [Elsevier](#) author policies as examples). If your article includes text or graphics from a work you published elsewhere, be sure that the quoted material does not exceed the bounds of your agreement with the initial publisher. You must also supply a credit



line/attribution to document the material's source and copyright holder; this text is usually supplied by the publisher.

### Copyright infringement

According to the Copyright Clearance Center, “copyright infringement occurs when a copyrighted work is reproduced, distributed, performed, publicly displayed, or made into a derivative work without the permission of the copyright owner.” [3–4] Copyright infringement can have serious legal, financial, and professional consequences.

### Using text copied from other sources

Plagiarism and copyright infringement are common problems in scientific and technical writing. [5–6] While scientific research builds on others' work, you may not understand the difference between paraphrasing information and importing someone else's content (see the [Plagiarism](#) section). Requesting permission also takes time that you may not have. If you're an author for whom English is a second language, you may find it faster and easier to use existing copy than to write in a foreign syntax—but that's still plagiarism. [7]

There are only two ways in which you may use copyrighted material without permission from its author or publisher: fair use and public domain.

#### *Fair use*

In the United States, whose copyright laws govern *Pharmaceutical Engineering*, the “fair use” legal doctrine permits *limited* use of copyright-protected works for purposes of discussion, analysis, or parody. In a scholarly or technical work, fair use allows excerpts of *short passages* of text for illustration, comment, or clarification. [8] In both cases, copied material must be marked as a quotation, and the source must be cited.

#### *Public domain*

Works in the public domain fall into two categories: 1) works for which the copyright has expired (Newton's *Principia*, for example), and 2) works deliberately published without copyright protection. Works in the public domain may be used without permission, although as with fair use, copied material must be marked as a quotation and the source must be credited.

- In the United States, most (but not all) work published by the federal government is in the public domain.
- Works produced by United Kingdom departments and agencies may be available under an open government license; [9] if not, they may be subject to Crown Copyright.
- Most European Union documents, [10] including EurLex data, [11] may be used without permission provided the source is acknowledged.

**Note:** *You must check each source to determine whether it is in the public domain.*

### Using copied graphics

Unless it's clear that a graphic is in the public domain, you must assume that it's protected and permission is required to use it.

Unfortunately, misconceptions about copyright and graphics also exist: [12]

***I've cited the source:*** Many people make this mistake with text as well. It is not permissible to use a figure (or portion of it) without permission even if you acknowledge the source. Unless the figure is in the public domain, using it without permission may well be copyright infringement.

***I'm not using much:*** It doesn't matter how large the original work is, or how much of it you're using. If you want to borrow a figure, you must have the copyright holder's permission.

***I'm going to modify it:*** Incorporating new material into a copyrighted graphic or figure may produce what's known as a "derivative work" (see the [Copyright infringement](#) section). This can only be done with authorization from the original holder, and must usually be credited as "adapted with permission."

***It's from a nonprofit organization:*** Nonprofit doesn't mean public domain. Some organizations, like ICH, allow material to be used without permission as long as they are identified as the copyright holder and any modifications to the original are noted. Others, like ISO and ISPE, require written permission to republish material. Be sure to check the organization's website for reuse parameters and contact information.

Securing permission to use a copyrighted work

We encourage authors to create original illustrations (including tables, charts, and graphs) for their articles whenever possible.

#### *Published material*

You must identify materials copied from (or based on) outside sources in your cover letter when you submit the article.

If the copied material has been published in a book or journal, the *Pharmaceutical Engineering* editorial staff will attempt to acquire the reprint permissions necessary.

To help us do so, you must supply the following information:

- **Title of the original work:** The book or journal in which the figure *first* appeared—and that may not be the work in which you found it. *Please be aware that you may have to do some research to find the original owner of an illustration.*
- **Author of the original work:** The person who wrote the book or article in which the figure first appeared. If your source is a book that contains chapters by multiple authors, please provide the name of the book author/editor and the chapter author.
- **Publisher:** The company (Elsevier, Springer, ACS) that published the book or journal in which the figure first appeared.
- **Publication information:**
  - Book: Chapter title, page, and/or figure number, edition and date of publication
  - Journal: Volume, issue, date of publication, page numbers

**Note:** *It will be difficult (if not impossible) to request reuse permission without this information. Material copied from works that are out of print or unidentifiable may be unusable.*

*Company-supplied material*

If you or one of your co-authors have included copied material supplied by a company, you must supply written consent from the company, along with any required attribution. (“Graphic of XYZ process © 2017 by PharmaCorp. Reprinted with permission.”)

If you include material copied from a company’s website or publication without their knowledge, you must request and be granted reuse permission before it can be republished in *Pharmaceutical Engineering*.

Once published in *Pharmaceutical Engineering*, articles may not be posted on any website, blog site, page, or reproduced in any form without written permission from ISPE.

If you want to share an article you’ve published, you have two options:

1. Once your article has been published, we can post it as an article on the [iSpeak blog](#). (*Note:* Longer articles may be published in two or more segments.) You’ll receive a link (or links) that you can post on your website, along with a summary of the article. This provides access for both ISPE members and nonmembers. [Here’s an example](#) of an article that was published as a multipart blog post.
2. You may order hard-copy reprints of most *Pharmaceutical Engineering* articles. Please contact the [managing editor](#) for more information about this option.

Author rights to reuse material

You may reuse any figures or graphics that appear in a published article and quote up to 10% of the article text in subsequent publications or presentations without requesting permission. All such use must include the following attribution:

Originally published in *Pharmaceutical Engineering* Vol XX, no. X (Month–Month YYYY). © ISPE YYYY. All rights reserved. Reprinted with permission.

Requests to republish larger sections of *Pharmaceutical Engineering* content should be submitted to the [managing editor](#).

## Part III: For more information

---

### Contact

If you have any questions regarding the article-submission process please contact:

- [Susan Sandler](#), editorial director +1-301-364-9212 x 415
- [Amy Loerch](#), managing editor: +1 813 960-2105 x 225

We look forward to working with you!

### References

1. United States Copyright Office. “Copyright in General.” <https://www.copyright.gov/help/faq/faq-general.html>
2. Das, Natasha, and Monica Panjabi. “Plagiarism: Why Is It Such a Big Issue for Medical Writers?” *Perspectives in Clinical Research* 2, no. 2 (April–June 2011): 67–71. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121267>
3. Copyright Clearance Center. Copyright FAQ. “What Is ‘Copyright Infringement’?” <http://support.copyright.com/index.php?action=article&id=240>
4. United States Copyright Office. “Copyright in Derivative Works and Compilations.” Circular 14. <https://www.copyright.gov/circs/circ14.pdf>
5. Masic, Izet. “Plagiarism in Scientific Publishing.” *Acta Informatica Medica* 20, no. 4 (December 2014): 208–213. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558294>
6. Butler, Declan. “Journals Step Up Plagiarism Policing.” *Nature* 466 (5 July 2010): 167. <http://www.nature.com/news/2010/100705/full/466167a.html>
7. Editorial. “The Insider’s Guide to Plagiarism.” *Nature Medicine* 15 (2009): 707. <http://www.nature.com/nm/journal/v15/n7/full/nm0709-707.html>
8. United States Copyright Office. “More Information on Fair Use.” <https://www.copyright.gov/fair-use/more-info.html>
9. United Kingdom National Archives. “Licensing for Re-Use.” <http://www.nationalarchives.gov.uk/information-management/re-using-public-sector-information/licensing-for-re-use>
10. Official Journal of the European Union. “Commission Decision of 12 December 2011 on the Reuse of Commission Documents.” 14 December 2011. <http://eur-lex.europa.eu/legal-content/en/TXT/?uri=CELEX%3A32011D0833>
11. European Union. Copyright Notice. <http://eur-lex.europa.eu/content/legal-notice/legal-notice.html#droits>
12. Jassin, Lloyd J. “Ten Common Copyright Permission Myths.” Copylaw.com. [http://www.copylaw.com/new\\_articles/copy\\_myths.html](http://www.copylaw.com/new_articles/copy_myths.html)